Literature DB >> 21933022

Transcriptional repression of Mad-Max complex by human umbilical cord blood stem cells downregulates extracellular signal-regulated kinase in glioblastoma.

Kiran Kumar Velpula1, Venkata Ramesh Dasari, Andrew J Tsung, Dzung H Dinh, Jasti S Rao.   

Abstract

Previously, we have shown that human umbilical cord blood stem cell (hUCBSC) treatment downregulate cyclin D1 in glioma cells. To study the cell cycle progression and investigate the upstream molecules regulating cyclin D1 expression, we analyzed the involvement of extracellular signal-regulated kinase (ERK) and its functionality after treatment with hUCBSC. We observed downregulation of pERK after hUCBSC treatment at both transcriptional and translational levels. Increased translocation of ERK from cytoplasm to the nucleus was observed in glioma cells, whereas hUCBSC cocultures with glioma cells showed suppressed nuclear translocation. This finding suggests that hUCBSC regulates ERK by suppressing its phosphorylation at phospho-Thr(202)/Tyr(204) retarding pERK nuclear translocation. ERK promoter analysis has shown c-Myc binding sites, indicative of possible transcriptional interactions that regulate cyclin D1 and ERK expression levels. Treatment of U251 and 5310 glioma cells with U0126, a MEK/ERK inhibitor receded pERK and c-Myc levels. In another experiment, U251 and 5310 cells treated with 10074-G5, c-Myc/Max inhibitor displayed reduction in pERK and c-Myc levels suggestive of a positive feedback loop between ERK/c-Myc/Max molecules. In the present study, we show that glioma cells exhibit abundant c-Myc expression and increased c-Myc/Max activity. In contrast, the glioma cells cocultured with hUCBSC demonstrated high Mad1 expression that competitively binds to Max to repress the c-Myc/Max mediated gene transcription. Our studies thus elucidate the potential role of hUCBSC in controlling glioma cell cycle progression and invasion by limiting Max binding to c-Myc, thus regulating the expression of glioma cell cycle and invasion associated molecules such as ERK, integrins via increased levels of Mad1 expression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21933022      PMCID: PMC3376458          DOI: 10.1089/scd.2011.0424

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  44 in total

Review 1.  The Max network gone mad.

Authors:  T A Baudino; J L Cleveland
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

2.  Elasticity of the human red blood cell skeleton.

Authors:  G Lenormand; S Hénon; A Richert; J Siméon; F Gallet
Journal:  Biorheology       Date:  2003       Impact factor: 1.875

Review 3.  Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.

Authors:  F Chang; L S Steelman; J T Lee; J G Shelton; P M Navolanic; W L Blalock; R A Franklin; J A McCubrey
Journal:  Leukemia       Date:  2003-07       Impact factor: 11.528

4.  The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc.

Authors:  S B McMahon; M A Wood; M D Cole
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

5.  Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion.

Authors:  H A Coller; C Grandori; P Tamayo; T Colbert; E S Lander; R N Eisenman; T R Golub
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

6.  The cytoplasmic domain of the integrin alpha9 subunit requires the adaptor protein paxillin to inhibit cell spreading but promotes cell migration in a paxillin-independent manner.

Authors:  B A Young; Y Taooka; S Liu; K J Askins; Y Yokosaki; S M Thomas; D Sheppard
Journal:  Mol Biol Cell       Date:  2001-10       Impact factor: 4.138

7.  Transcriptional activation of cyclin D1 promoter by FAK contributes to cell cycle progression.

Authors:  J Zhao; R Pestell; J L Guan
Journal:  Mol Biol Cell       Date:  2001-12       Impact factor: 4.138

8.  Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results.

Authors:  Frederick F Lang; Janet M Bruner; Gregory N Fuller; Kenneth Aldape; Michael D Prados; Susan Chang; Mitchel S Berger; Michael W McDermott; Sandeep M Kunwar; Larry R Junck; William Chandler; James A Zwiebel; Richard S Kaplan; W K Alfred Yung
Journal:  J Clin Oncol       Date:  2003-07-01       Impact factor: 44.544

9.  Ets-1 and integrin beta3 for lung metastasis from colorectal cancer.

Authors:  Takahiro Sato; Atsuo Miwa
Journal:  APMIS       Date:  2002-04       Impact factor: 3.205

10.  PKCalpha-mediated ERK, JNK and p38 activation regulates the myogenic program in human rhabdomyosarcoma cells.

Authors:  Annunziata Mauro; Carmela Ciccarelli; Paola De Cesaris; Arianna Scoglio; Marina Bouché; Mario Molinaro; Angelo Aquino; Bianca Maria Zani
Journal:  J Cell Sci       Date:  2002-09-15       Impact factor: 5.285

View more
  9 in total

1.  GDNF Promotes Astrocyte Abnormal Proliferation and Migration Through the GFRα1/RET/MAPK/pCREB/LOXL2 Signaling Axis.

Authors:  Miaomiao Wang; Xiao Han; Wei Zha; Xiaoyu Wang; Liyun Liu; Zimu Li; Yefeng Shi; Xugang Kan; Gui Wang; Dianshuai Gao; Baole Zhang
Journal:  Mol Neurobiol       Date:  2022-08-04       Impact factor: 5.682

2.  Galectin-1 activates carbonic anhydrase IX and modulates glioma metabolism.

Authors:  Maheedhara R Guda; Andrew J Tsung; Swapna Asuthkar; Kiran K Velpula
Journal:  Cell Death Dis       Date:  2022-06-30       Impact factor: 9.685

3.  EGFR and c-Met Cross Talk in Glioblastoma and Its Regulation by Human Cord Blood Stem Cells.

Authors:  Kiran Kumar Velpula; Venkata Ramesh Dasari; Swapna Asuthkar; Bharathi Gorantla; Andrew J Tsung
Journal:  Transl Oncol       Date:  2012-10-01       Impact factor: 4.243

4.  Radiation-induced hypomethylation triggers urokinase plasminogen activator transcription in meningioma cells.

Authors:  Kiran Kumar Velpula; Venkateswara Rao Gogineni; Arun Kumar Nalla; Dzung H Dinh; Jasti S Rao
Journal:  Neoplasia       Date:  2013-02       Impact factor: 5.715

5.  Cord blood stem cells revert glioma stem cell EMT by down regulating transcriptional activation of Sox2 and Twist1.

Authors:  Kiran Kumar Velpula; Venkata Ramesh Dasari; Andrew J Tsung; Dzung H Dinh; Jasti S Rao
Journal:  Oncotarget       Date:  2011-12

6.  Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor.

Authors:  Emily Jane Gallagher; Nyosha Alikhani; Aviva Tobin-Hess; Jeffrey Blank; Nicholas J Buffin; Zara Zelenko; Norbert Tennagels; Ulrich Werner; Derek LeRoith
Journal:  Diabetes       Date:  2013-07-08       Impact factor: 9.461

7.  Mxi1-0 regulates the growth of human umbilical vein endothelial cells through extracellular signal-regulated kinase 1/2 (ERK1/2) and interleukin-8 (IL-8)-dependent pathways.

Authors:  Weiling Wu; Zhenzhen Hu; Feng Wang; Hao Gu; Xiuqin Jiang; Jinjin Xu; Xi Zhan; Datong Zheng; Zhengdong Zhang
Journal:  PLoS One       Date:  2017-06-02       Impact factor: 3.240

Review 8.  Mesenchymal stem/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications.

Authors:  Wei-Zhan Zhuang; Yi-Heng Lin; Long-Jyun Su; Meng-Shiue Wu; Han-Yin Jeng; Huan-Cheng Chang; Yen-Hua Huang; Thai-Yen Ling
Journal:  J Biomed Sci       Date:  2021-04-14       Impact factor: 8.410

9.  GLUT1 and TUBB4 in Glioblastoma Could be Efficacious Targets.

Authors:  Maheedhara R Guda; Collin M Labak; Sara Ibrahim Omar; Swapna Asuthkar; Subra Airala; Jack Tuszynski; Andrew J Tsung; Kiran K Velpula
Journal:  Cancers (Basel)       Date:  2019-09-05       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.